TLR3 and neoplasm: To exclude anti-tumor activity of polyplexes due to siRNA-mediated activation of Toll-like receptor 3 (TLR3) [33,34], PSCA-engineered HEK-BluehTLR3/PSCA reporter cells were treated with polyplexes loaded with siSurv.